Is Iron Mountain (IRM) stock a good buy or sell?
Iron Mountain has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating. According to analysts' consensus price target of $33.00, Iron Mountain has a forecasted downside of 36.9% from its current price of $52.33.
What is Iridium Communications' (IRDM) stock symbol?
Iridium Communications trades on the NASDAQ under the ticker symbol "IRDM." Who are Iridium Communications' major shareholders? Iridium Communications' stock is owned by a variety of retail and institutional investors.
How has IRDM's stock performed during covid-19?
Iridium Communications' stock was trading at $23.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IRDM shares have increased by 105.3% and is now trading at $47.27.
Where can I buy IRDM shares?
Shares of IRDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
See more
Is ITRM stock a good buy?
Iterum Therapeutics PLC (NASDAQ:ITRM) The 1 analysts offering 12-month price forecasts for Iterum Therapeutics PLC have a median target of 1.00, with a high estimate of 1.00 and a low estimate of 1.00. The median estimate represents a +262.71% increase from the last price of 0.28.
Why is ITRM stock dropping?
Shares of Iterum Therapeutics plc dropped Monday after the company announced that it will not get approval for the current form of its new drug application for oral sulopenem.
What is the future of ITRM?
On average, analysts forecast that ITRM's EPS will be -$0.22 for 2022, with the lowest EPS forecast at -$0.22, and the highest EPS forecast at -$0.22. On average, analysts forecast that ITRM's EPS will be -$0.27 for 2023, with the lowest EPS forecast at -$0.27, and the highest EPS forecast at -$0.27.
What does Iterum therapeutics do?
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens.